Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
0.8982
+0.0478 (5.63%)
Apr 3, 2025, 11:46 AM EST
Interpace Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 46.93 | 40.21 | 31.84 | 33.12 | 32.4 | Upgrade
|
| Revenue Growth (YoY) | 16.69% | 26.31% | -3.86% | 2.22% | 33.77% | Upgrade
|
| Cost of Revenue | 17 | 16.31 | 13.61 | 14.31 | 21.67 | Upgrade
|
| Gross Profit | 29.93 | 23.9 | 18.23 | 18.8 | 10.73 | Upgrade
|
| Selling, General & Admin | 21.14 | 19.6 | 20.1 | 19.88 | 27.45 | Upgrade
|
| Research & Development | 0.68 | 0.64 | 0.7 | 1.49 | 2.8 | Upgrade
|
| Operating Expenses | 21.82 | 21.09 | 22.07 | 24.57 | 34.7 | Upgrade
|
| Operating Income | 8.11 | 2.81 | -3.84 | -5.76 | -23.98 | Upgrade
|
| Interest Expense | -0.66 | -1.01 | -1.01 | -1.04 | -0.55 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.5 | -0.67 | -1.21 | -0.38 | 0.47 | Upgrade
|
| EBT Excluding Unusual Items | 6.95 | 1.14 | -6.06 | -7.18 | -24.06 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.9 | -2.58 | Upgrade
|
| Other Unusual Items | - | -0.01 | 0.22 | 0.34 | 0.49 | Upgrade
|
| Pretax Income | 6.95 | 1.13 | -5.84 | -7.74 | -26.15 | Upgrade
|
| Income Tax Expense | 0 | 0.02 | 0.03 | -0.71 | 0.05 | Upgrade
|
| Earnings From Continuing Operations | 6.95 | 1.11 | -5.87 | -7.04 | -26.2 | Upgrade
|
| Earnings From Discontinued Operations | -0.24 | -0.31 | -16.09 | -7.91 | -0.25 | Upgrade
|
| Net Income | 6.7 | 0.8 | -21.96 | -14.94 | -26.45 | Upgrade
|
| Preferred Dividends & Other Adjustments | -0.46 | - | - | - | 3.03 | Upgrade
|
| Net Income to Common | 7.17 | 0.8 | -21.96 | -14.94 | -29.48 | Upgrade
|
| Net Income Growth | 735.66% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 260.54% | 2.97% | 2.49% | 2.63% | 7.56% | Upgrade
|
| EPS (Basic) | 1.63 | 0.19 | -5.18 | -3.61 | -7.32 | Upgrade
|
| EPS (Diluted) | 0.39 | 0.18 | -5.18 | -3.61 | -7.32 | Upgrade
|
| EPS Growth | 120.43% | - | - | - | - | Upgrade
|
| Free Cash Flow | 3.77 | 3.32 | -8.01 | -9.07 | -15.55 | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.76 | -1.89 | -2.19 | -3.86 | Upgrade
|
| Gross Margin | 63.77% | 59.44% | 57.26% | 56.78% | 33.10% | Upgrade
|
| Operating Margin | 17.28% | 6.99% | -12.06% | -17.41% | -74.01% | Upgrade
|
| Profit Margin | 15.27% | 1.99% | -68.97% | -45.12% | -91.01% | Upgrade
|
| Free Cash Flow Margin | 8.03% | 8.25% | -25.17% | -27.40% | -48.01% | Upgrade
|
| EBITDA | 8.41 | 3.84 | -1.28 | -0.39 | -18.48 | Upgrade
|
| EBITDA Margin | 17.92% | 9.54% | -4.02% | -1.18% | -57.03% | Upgrade
|
| D&A For EBITDA | 0.3 | 1.03 | 2.56 | 5.37 | 5.5 | Upgrade
|
| EBIT | 8.11 | 2.81 | -3.84 | -5.76 | -23.98 | Upgrade
|
| EBIT Margin | 17.28% | 6.99% | -12.06% | -17.41% | -74.01% | Upgrade
|
| Effective Tax Rate | 0.06% | 1.51% | - | - | - | Upgrade
|
Updated Nov 8, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.